Neurotech Pharmaceuticals, Inc.
http://www.neurotechusa.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Neurotech Pharmaceuticals, Inc.
Cancer, Gene Therapy Top US FDA’s Second Half 2024 User Fee Calendar
Novel agents in immuno-oncology headline the drug center’s upcoming goal dates, while gene therapies make up most of the biologic center’s workload.
Rapport Navigates Rough IPO Market With Well-Received Offering
Rapport Therapeutics launched an initial public offering in the middle of a proposed price range, and the CNS-focused company closed slightly above its IPO price on its first day of trading.
BIO Notebook: Califf On RWE, Industry Execs On Growing Therapeutic Areas, And More
Insights from Day Four of the BIO International Convention include FDA commissioner Califf on the state of real-world evidence and how it impacts IRA negotiations, Roche's interest in cardiovascular/metabolic assets, Merck's plans in immunology, and industry's rising interest in neuropsychiatry.
BIO Notebook: Califf On RWE, Industry Execs On Growing Therapeutic Areas, And More
Insights from Day Four of the BIO International Convention include FDA commissioner Califf on the state of real-world evidence and how it impacts IRA negotiations, Roche's interest in cardiovascular/metabolic assets, Merck's plans in immunology, and industry's rising interest in neuropsychiatry.
Company Information
- Industry
- Medical Devices
-
Medical Devices
- Biomaterials
-
Biotechnology
-
Drug Discovery Tools
- ADMET
-
Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice